Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases
A total of 16 claims covering novel compounds, pharmaceutical composition and use were granted with a term lasting to December 2019. This is the first patent issued for the Company's WBI-1000 series of compounds in a cluster of national applications pending in jurisdictions including Australia, Canada, China, Europe, Japan, Korea and the United States.
"This latest patent strengthens the Company's growing proprietary position in pre-targeted therapies that seek to address unmet medical needs in inflammatory/autoimmune diseases," said John Webster, President & CEO of Welichem. "It also provides intellectual property protection for our lead product, WBI-1001, part of a group of pharmaceutical compounds from symbiotic organisms that have great potential to treat a number of diseases and disorders," he added. The Company currently plans to begin formal clinical testing of the drug in early 2006.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.